Form 4: Guardant Health CMO's RSU Vesting & Tax Withholding

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of performance-based and time-based restricted stock units, alongside shares withheld for tax obligations.

Summary

• Craig Eagle, Chief Medical Officer of Guardant Health, Inc. (GH), reported transactions on March 15, 2026.
• Acquired 13,712 shares of Common Stock from the vesting of performance-based Restricted Stock Units (RSUs) granted on June 7, 2023, after achieving the second tranche performance metric.
• Acquired an additional 1,402 shares of Common Stock from the vesting of time-based RSUs granted on June 9, 2023, as part of a three-year vesting schedule.
• 7,661 shares were disposed of (retained by the company) at $85.49 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Craig Eagle beneficially owns 66,380 shares of Common Stock directly.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the achievement of performance metrics and routine executive compensation, which generally indicates stability in management incentives.

Positives

• Vesting of 13,712 performance-based restricted stock units indicates the achievement of a performance metric.
• Vesting of 1,402 time-based restricted stock units reflects continued tenure and compensation.

Negatives

• 7,661 shares were withheld by the company to cover tax obligations, reducing the net shares received by the officer.

Future Outlook

The remaining 67% of the time-based restricted stock units granted on June 9, 2023, will vest in equal quarterly installments over the remaining two-year period after June 15, 2024.

Industry Context

StockSavvy.ai notes that insider transaction filings like Form 4 are routine disclosures for publicly traded companies, reflecting standard executive compensation practices involving equity awards. The vesting of performance-based RSUs is a positive signal regarding the achievement of internal company goals, aligning executive incentives with shareholder value.

Comparison to Industry Standards

• These types of RSU grants and vesting schedules are standard practice across the biotechnology and healthcare technology sectors for executive compensation, similar to companies like Illumina or Exact Sciences, aiming to retain talent and align long-term interests.
• The withholding of shares for tax purposes is also a common mechanism for settling tax liabilities upon vesting.

Stakeholder Impact

• Shareholders: The vesting of performance-based units could be seen as a positive signal regarding management's achievement of company goals. The overall impact is neutral to slightly positive as it reflects standard compensation practices.
• Employees: Reflects standard executive compensation practices, which can influence broader employee compensation structures and morale.

Next Steps

• Remaining 67% of the time-based restricted stock units granted on June 9, 2023, will vest in equal quarterly installments over the remaining two-year period after June 15, 2024.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of restricted stock units and subsequent tax withholding, executed under a pre-arranged 10b5-1 plan. Such transactions are standard executive compensation events and do not typically provide new fundamental information to warrant a change in investment thesis. The achievement of performance metrics for some RSUs is a minor positive, but the overall impact on the company's valuation or future prospects is negligible. Therefore, a "hold" recommendation is appropriate, as the filing does not present compelling reasons to buy or sell based solely on this information.

Keywords

Guardant Health, GH, Craig Eagle, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Officer Compensation, Beneficial Ownership, Rule 10b5-1